Cardiology

Original Research

Balloon Valvuloplasty as an Initial Palliation in the Treatment of Newborns and Young Infants with Severely Symptomatic Tetralogy of Fallot

Wu E.-T. · Wang J.-K. · Lee W.-L. · Chang C.-C. · Wu M.-H.

Author affiliations

Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC

Related Articles for ""

Cardiology 2006;105:52–56

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: June 07, 2005
Accepted: August 21, 2005
Published online: November 24, 2005
Issue release date: November 2005

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 1

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Abstract

Background: Balloon valvuloplasty in infants with symptomatic tetralogy of Fallot (TOF) may increase the pulmonary flow and prompt the growth of pulmonary arteries. Method: From 1994 to 2002, percutaneous transluminal balloon valvuloplasty (PTPV) was performed in 22 consecutive newborns and young infants (<3 months of age) with TOF. The indication included severe hypoxemia (systemic oxygen saturation below 75%, 10 cases) and repeated hypoxic spells (12 cases). The age at PTPV was 8–88 days (38 ± 34, median 27) and the body weight 2–5 kg (3.45 ± 1.15, median 3). A balloon catheter (4– 7 mm in diameter and 2 cm in length) was used to dilate the pulmonary valve. Results: No major procedure-related complications occurred. The systemic oxygen saturation increased significantly (14 ± 9%). A subsequent palliative shunt operation was avoided in 12 patients (54.5%), but 10 still needed operation (median 11 days after the PTPV). The presence of recurrent hypoxic spells before PTPV was the most important indicator for PTPV failure (p = 0.02). Conclusion: PTPV was safe and effective for symptomatic newborns and young infants with TOF, but a palliative shunt operation was still needed due to short effect, especially in those with recurrent spells before the dilation.

© 2006 S. Karger AG, Basel




Related Articles:


References

  1. Kan JS, White RI Jr, Mitchell SE, Gardner TJ: Percutaneous balloon valvuloplasty: a new method for treating congenital pulmonary-valve stenosis. N Engl J Med 1982;307:540–542.
  2. McCredie RM, Swinburn MJ, Lee CL, Warner G: Balloon dilatation pulmonary valvuloplasty in pulmonary stenosis. Aust N Z J Med 1986;16:20–23.
  3. Sluysmans T, Neven B, Rubay J, Lintermans J, Ovaert C, Mucumbitsi J, Shango P, Stijns M, Vliers A: Early balloon dilatation of the pulmonary valve in infants with tetralogy of Fallot. Risks and benefits. Circulation 1995;91:1506–1511.
  4. Sreeram N, Saleem M, Jackson M, Peart I, McKay R, Arnold R, Walsh K: Results of balloon pulmonary valvuloplasty as a palliative procedure in tetralogy of Fallot. J Am Coll Cardiol 1991;18:159–165.
  5. Godart F, Rey C, Prat A, Muilwijk C, Francart C, Vaksmann G, Breviere GM: Early and late results and the effects on pulmonary arteries of balloon dilatation of the right ventricular outflow tract in tetralogy of Fallot. Eur Heart J 1998;19:595–600.
  6. Van Arsdell GS, Maharaj GS, Tom J, Rao VK, Coles JG, Freedom RM, Williams WG, McCrindle BW: What is the optimal age for repair of tetralogy of Fallot? Circulation 2000;102 (suppl 3):III123–III129.
  7. Pome G, Rossi C, Colucci V, Passini L, Morello M, Taglieri C, Pezzano A, Figini A, Pellegrini A: Late reoperations after repair of tetralogy of Fallot. Eur J Cardiothorac Surg 1992;6:31–35.
  8. Gladman G, McCrindle BW, Williams WG, Freedom RM, Benson LN: The modified Blalock-Taussig shunt: clinical impact and morbidity in Fallot’s tetralogy in the current era. J Thorac Cardiovasc Surg 1997;114:25–30.
  9. Fraser CD Jr, McKenzie ED, Cooley DA: Tetralogy of Fallot: surgical management individualized to the patient. Ann Thorac Surg 2001;71:1556–1561; discussion 1561–1553.
  10. Seipelt RG, Vazquez-Jimenez JF, Sachweh JS, Seghaye MC, Messmer BJ: Antegrade palliation for diminutive pulmonary arteries in Tetralogy of Fallot. Eur J Cardiothorac Surg 2002;21:721–724; discussion 724.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: June 07, 2005
Accepted: August 21, 2005
Published online: November 24, 2005
Issue release date: November 2005

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 1

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP